Workplace Burnout Among Oncologists Has Risen: What Can be Done?
A recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.
Related Articles
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Data Show Racial/Ethnic Disparities in Pediatric Brain Cancer Survival
Clinical trial access alone appears to be insufficient in overcoming the worse survival outcomes observed in Black and Hispanic pediatric populations.
What Does It Mean to Experience Workplace Burnout as an Oncologist?
Workplace burnout in medicine and oncology can lead to stress, exhaustion, fatigue, and a lack of interest in work, according to Eric P. Winer, MD.
FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera
The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.
Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma
Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.
FACE-OFF: Northwestern vs University of Chicago
Experts from Northwestern University and the University of Chicago present data and debate treatment practices in the non–small cell lung cancer space.
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
Multidisciplinary Breast Cancer Clinic Improves Time to First Treatment
Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.
FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.
JNJ-1900 Demonstrates Safety, Feasibility in Advanced Pancreatic Cancer
Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.